{"pmid":32270359,"title":"Acute stroke management pathway during Coronavirus-19 pandemic.","text":["Acute stroke management pathway during Coronavirus-19 pandemic.","Since the outbreak of the COVID-19 epidemic which in our region, Veneto (Italy), dates back to February, we were confronted with several challenges, but with a constant aim of keeping our Stroke Unit COVID-free. For this reason, in addition to creating a dedicated hot-spot as a pre-triage just outside the Emergency Department, together with the Neuroradiology Unit we obtained a mobile CT unit that could be used by COVID-positive or COVID-suspected patients. Furthermore, thanks to the collaboration with colleagues from different specialties (Infectious Disease, Internal Medicine, Intensive Care, Emergency Medicine), dedicated areas for COVID patients were activated. This led to a substantial change of our acute stoke management pathway. As the number of COVID patients increased, and the WHO declared a state of pandemic, this new stroke pathway has been fully tested. We would like to share our experience and send a clear message to keep a high attention on stroke as an emergency condition, because we have observed a decreased number of patients with minor strokes and TIAs, longer onset-to-door and door-to-treatment times for major strokes, and a reduced number of transfers from spokes. We strongly believe that the general population and family doctors are rightly focused on COVID. However, to remain at home with stroke symptoms does not mean to \"stay safe at home\".","Neurol Sci","Baracchini, Claudio","Pieroni, Alessio","Viaro, Federica","Cianci, Vito","Cattelan, Anna M","Tiberio, Ivo","Munari, Marina","Causin, Francesco","32270359"],"abstract":["Since the outbreak of the COVID-19 epidemic which in our region, Veneto (Italy), dates back to February, we were confronted with several challenges, but with a constant aim of keeping our Stroke Unit COVID-free. For this reason, in addition to creating a dedicated hot-spot as a pre-triage just outside the Emergency Department, together with the Neuroradiology Unit we obtained a mobile CT unit that could be used by COVID-positive or COVID-suspected patients. Furthermore, thanks to the collaboration with colleagues from different specialties (Infectious Disease, Internal Medicine, Intensive Care, Emergency Medicine), dedicated areas for COVID patients were activated. This led to a substantial change of our acute stoke management pathway. As the number of COVID patients increased, and the WHO declared a state of pandemic, this new stroke pathway has been fully tested. We would like to share our experience and send a clear message to keep a high attention on stroke as an emergency condition, because we have observed a decreased number of patients with minor strokes and TIAs, longer onset-to-door and door-to-treatment times for major strokes, and a reduced number of transfers from spokes. We strongly believe that the general population and family doctors are rightly focused on COVID. However, to remain at home with stroke symptoms does not mean to \"stay safe at home\"."],"journal":"Neurol Sci","authors":["Baracchini, Claudio","Pieroni, Alessio","Viaro, Federica","Cianci, Vito","Cattelan, Anna M","Tiberio, Ivo","Munari, Marina","Causin, Francesco"],"date":"2020-04-10T11:00:00Z","year":2020,"_id":"32270359","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s10072-020-04375-9","keywords":["Acute stroke","COVID-19","Coronavirus","Stroke Unit"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1663620083174342656,"score":7.9164424,"similar":[{"pmid":32233980,"title":"Protected Code Stroke: Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic.","text":["Protected Code Stroke: Hyperacute Stroke Management During the Coronavirus Disease 2019 (COVID-19) Pandemic.","Background and Purpose- Hyperacute assessment and management of patients with stroke, termed code stroke, is a time-sensitive and high-stakes clinical scenario. In the context of the current Coronavirus Disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus, the ability to deliver timely and efficacious care must be balanced with the risk of infectious exposure to the clinical team. Furthermore, rapid and effective stroke care remains paramount to achieve maximal functional recovery for those needing admission and to triage care appropriately for those who may be presenting with neurological symptoms but have an alternative diagnosis. Methods- Available resources, COVID-19-specific infection prevention and control recommendations, and expert consensus were used to identify clinical screening criteria for patients and provide the required nuanced considerations for the healthcare team, thereby modifying the conventional code stroke processes to achieve a protected designation. Results- A protected code stroke algorithm was developed. Features specific to prenotification and clinical status of the patient were used to define precode screening. These include primary infectious symptoms, clinical, and examination features. A focused framework was then developed with regard to a protected code stroke. We outline the specifics of personal protective equipment use and considerations thereof including aspects of crisis resource management impacting team role designation and human performance factors during a protected code stroke. Conclusions- We introduce the concept of a protected code stroke during a pandemic, as in the case of COVID-19, and provide a framework for key considerations including screening, personal protective equipment, and crisis resource management. These considerations and suggested algorithms can be utilized and adapted for local practice.","Stroke","Khosravani, Houman","Rajendram, Phavalan","Notario, Lowyl","Chapman, Martin G","Menon, Bijoy K","32233980"],"abstract":["Background and Purpose- Hyperacute assessment and management of patients with stroke, termed code stroke, is a time-sensitive and high-stakes clinical scenario. In the context of the current Coronavirus Disease 2019 (COVID-19) pandemic caused by the SARS-CoV-2 virus, the ability to deliver timely and efficacious care must be balanced with the risk of infectious exposure to the clinical team. Furthermore, rapid and effective stroke care remains paramount to achieve maximal functional recovery for those needing admission and to triage care appropriately for those who may be presenting with neurological symptoms but have an alternative diagnosis. Methods- Available resources, COVID-19-specific infection prevention and control recommendations, and expert consensus were used to identify clinical screening criteria for patients and provide the required nuanced considerations for the healthcare team, thereby modifying the conventional code stroke processes to achieve a protected designation. Results- A protected code stroke algorithm was developed. Features specific to prenotification and clinical status of the patient were used to define precode screening. These include primary infectious symptoms, clinical, and examination features. A focused framework was then developed with regard to a protected code stroke. We outline the specifics of personal protective equipment use and considerations thereof including aspects of crisis resource management impacting team role designation and human performance factors during a protected code stroke. Conclusions- We introduce the concept of a protected code stroke during a pandemic, as in the case of COVID-19, and provide a framework for key considerations including screening, personal protective equipment, and crisis resource management. These considerations and suggested algorithms can be utilized and adapted for local practice."],"journal":"Stroke","authors":["Khosravani, Houman","Rajendram, Phavalan","Notario, Lowyl","Chapman, Martin G","Menon, Bijoy K"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32233980","week":"202014|Mar 30 - Apr 05","doi":"10.1161/STROKEAHA.120.029838","keywords":["COVID-19","algorithms","consensus","pandemics","stroke"],"source":"PubMed","topics":["Diagnosis","Prevention"],"weight":1,"_version_":1663352135593492481,"score":250.38289},{"pmid":32233972,"title":"Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic.","text":["Temporary Emergency Guidance to US Stroke Centers During the COVID-19 Pandemic.","During this unprecedented time of extraordinary stress on the US healthcare system, the AHA/ASA Stroke Council-as individuals in our localities and together as an entity at the national level-acknowledge the mounting concern regarding optimal stroke care during the COVID-19 pandemic among vascular neurologists and those clinicians who care for patients with stroke. We therefore seek to provide guidance for the care of stroke patients in the midst of the crisis. Ordinarily, national recommendations go through a rigorous process of development, refinement, peer review, and thoughtful promulgation. None of that is possible at this time, yet we believe there is a substantial need for a broad policy statement that reflects both the commonality of the pandemic across the US and the individual variability necessary at local sites. We issue this temporary statement as an interim stopgap opinion, pending a more thorough and considered process.","Stroke","32233972"],"abstract":["During this unprecedented time of extraordinary stress on the US healthcare system, the AHA/ASA Stroke Council-as individuals in our localities and together as an entity at the national level-acknowledge the mounting concern regarding optimal stroke care during the COVID-19 pandemic among vascular neurologists and those clinicians who care for patients with stroke. We therefore seek to provide guidance for the care of stroke patients in the midst of the crisis. Ordinarily, national recommendations go through a rigorous process of development, refinement, peer review, and thoughtful promulgation. None of that is possible at this time, yet we believe there is a substantial need for a broad policy statement that reflects both the commonality of the pandemic across the US and the individual variability necessary at local sites. We issue this temporary statement as an interim stopgap opinion, pending a more thorough and considered process."],"journal":"Stroke","date":"2020-04-03T11:00:00Z","year":2020,"_id":"32233972","week":"202014|Mar 30 - Apr 05","doi":"10.1161/STROKEAHA.120.030023","keywords":["American Stroke Association","Corona Virus Disease 2019"],"source":"PubMed","locations":["US"],"countries":["United States"],"countries_codes":["USA|United States"],"weight":0,"_version_":1663352135688912896,"score":217.69078},{"pmid":32246838,"title":"Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy.","text":["Hospital surge capacity in a tertiary emergency referral centre during the COVID-19 outbreak in Italy.","The first person-to-person transmission of the 2019-novel coronavirus in Italy on 21 February 2020 led to an infection chain that represents one of the largest known COVID-19 outbreaks outside Asia. In Northern Italy in particular, we rapidly experienced a critical care crisis due to a shortage of intensive care beds, as we expected according to data reported in China. Based on our experience of managing this surge, we produced this review to support other healthcare services in preparedness and training of hospitals during the current coronavirus outbreak. We had a dedicated task force that identified a response plan, which included: (1) establishment of dedicated, cohorted intensive care unit(s) (ICU) for COVID-19-positive patients; (2) design of appropriate procedures for pre-triage, diagnosis and isolation of suspected and confirmed cases; and (3) training of all staff to work in the dedicated ICU in personal protective equipment use and patient management. Hospital multidisciplinary and departmental collaboration was needed to work on all principles of surge capacity, including: space definition; supplies provision; staff recruitment; and ad-hoc training. Dedicated protocols were applied where full isolation of spaces, staff and patients was implemented. Opening the unit and the whole hospital emergency process required a multidisciplinary, multilevel involvement of healthcare providers and hospital managers all working towards a common goal: patient care and hospital safety. Hospitals should be prepared to face severe disruptions to their routine and it is very likely that protocols and procedures might require re-discussion and update on a daily basis.","Anaesthesia","Carenzo, L","Costantini, E","Greco, M","Barra, F L","Rendiniello, V","Mainetti, M","Bui, R","Zanella, A","Grasselli, G","Lagioia, M","Protti, A","Cecconi, M","32246838"],"abstract":["The first person-to-person transmission of the 2019-novel coronavirus in Italy on 21 February 2020 led to an infection chain that represents one of the largest known COVID-19 outbreaks outside Asia. In Northern Italy in particular, we rapidly experienced a critical care crisis due to a shortage of intensive care beds, as we expected according to data reported in China. Based on our experience of managing this surge, we produced this review to support other healthcare services in preparedness and training of hospitals during the current coronavirus outbreak. We had a dedicated task force that identified a response plan, which included: (1) establishment of dedicated, cohorted intensive care unit(s) (ICU) for COVID-19-positive patients; (2) design of appropriate procedures for pre-triage, diagnosis and isolation of suspected and confirmed cases; and (3) training of all staff to work in the dedicated ICU in personal protective equipment use and patient management. Hospital multidisciplinary and departmental collaboration was needed to work on all principles of surge capacity, including: space definition; supplies provision; staff recruitment; and ad-hoc training. Dedicated protocols were applied where full isolation of spaces, staff and patients was implemented. Opening the unit and the whole hospital emergency process required a multidisciplinary, multilevel involvement of healthcare providers and hospital managers all working towards a common goal: patient care and hospital safety. Hospitals should be prepared to face severe disruptions to their routine and it is very likely that protocols and procedures might require re-discussion and update on a daily basis."],"journal":"Anaesthesia","authors":["Carenzo, L","Costantini, E","Greco, M","Barra, F L","Rendiniello, V","Mainetti, M","Bui, R","Zanella, A","Grasselli, G","Lagioia, M","Protti, A","Cecconi, M"],"date":"2020-04-05T11:00:00Z","year":2020,"_id":"32246838","week":"202014|Mar 30 - Apr 05","doi":"10.1111/anae.15072","source":"PubMed","locations":["Italy","China"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1663352135836762115,"score":169.7247},{"pmid":32267998,"title":"Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series.","text":["Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series.","A hallmark of severe COVID-19 is coagulopathy, with 71.4% of patients who die of COVID-19 meeting ISTH criteria for disseminated intravascular coagulation (DIC) while only 0.6% of patients who survive meet these criteria (1). Additionally, it has become clear that this is not a bleeding diathesis but rather a predominantly pro-thrombotic DIC with high venous thromboembolism rates, elevated D-dimer levels, high fibrinogen levels in concert with low anti-thrombin levels, and pulmonary congestion with microvascular thrombosis and occlusion on pathology in addition to mounting experience with high rates of central line thrombosis and vascular occlusive events (e.g. ischemic limbs, strokes, etc.) observed by those who care for critically ill COVID-19 patients (1-7). There is evidence in both animals and humans that fibrinolytic therapy in Acute Lung Injury and ARDS improves survival, which also points to fibrin deposition in the pulmonary microvasculature as a contributory cause of ARDS and would be expected to be seen in patients with ARDS and concomitant diagnoses of DIC on their laboratory values such as what is observed in more than 70% of those who die of COVID-19 (8-10).","J Thromb Haemost","Wang, Janice","Hajizadeh, Negin","Moore, Ernest E","McIntyre, Robert C","Moore, Peter K","Veress, Livia A","Yaffe, Michael B","Moore, Hunter B","Barrett, Christopher D","32267998"],"abstract":["A hallmark of severe COVID-19 is coagulopathy, with 71.4% of patients who die of COVID-19 meeting ISTH criteria for disseminated intravascular coagulation (DIC) while only 0.6% of patients who survive meet these criteria (1). Additionally, it has become clear that this is not a bleeding diathesis but rather a predominantly pro-thrombotic DIC with high venous thromboembolism rates, elevated D-dimer levels, high fibrinogen levels in concert with low anti-thrombin levels, and pulmonary congestion with microvascular thrombosis and occlusion on pathology in addition to mounting experience with high rates of central line thrombosis and vascular occlusive events (e.g. ischemic limbs, strokes, etc.) observed by those who care for critically ill COVID-19 patients (1-7). There is evidence in both animals and humans that fibrinolytic therapy in Acute Lung Injury and ARDS improves survival, which also points to fibrin deposition in the pulmonary microvasculature as a contributory cause of ARDS and would be expected to be seen in patients with ARDS and concomitant diagnoses of DIC on their laboratory values such as what is observed in more than 70% of those who die of COVID-19 (8-10)."],"journal":"J Thromb Haemost","authors":["Wang, Janice","Hajizadeh, Negin","Moore, Ernest E","McIntyre, Robert C","Moore, Peter K","Veress, Livia A","Yaffe, Michael B","Moore, Hunter B","Barrett, Christopher D"],"date":"2020-04-09T11:00:00Z","year":2020,"_id":"32267998","week":"202015|Apr 06 - Apr 12","doi":"10.1111/jth.14828","keywords":["Acute Respiratory Distress Syndrome (ARDS)","COVID-19","Case Report","Fibrinolysis","Tissue Plasminogen Activator (tPA)"],"source":"PubMed","topics":["Case Report"],"weight":1,"_version_":1663609715835273216,"score":151.34358},{"pmid":32191623,"title":"The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks.","text":["The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks.","Coronavirus disease 2019, abbreviated to COVID-19 and sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the latest biological hazard to assume the relevance of insidious worldwide threat. One obvious question that is now engaging the minds of many scientists and healthcare professionals is whether and eventually how laboratory medicine could efficiently contribute to counteract this and other (future) viral outbreaks. Despite there being evidence that laboratory tests are vital throughout many clinical pathways, there are at least three major areas where in vitro diagnostics can also provide essential contributions to diagnostic reasoning and managed care of patients with suspected or confirmed SARS-CoV-2 infection. These include etiological diagnosis, patient monitoring, as well as epidemiologic surveillance. Nonetheless, some structural and practical aspects may generate substantial hurdles in providing timely and efficient response to this infectious emergency, which basically include inadequate (insufficient) environment and shortage of technical and human resources for facing enhanced volume of tests on many infected patients, some of whom are with severe disease. Some proactive and reactive strategies may hence be identified to confront this serious healthcare challenge, which entail major investments on conventional laboratory resources, reinforcement of regional networks of clinical laboratories, installation of mobile laboratories, as well as being proactive in establishing laboratory emergency plans.","Clin Chem Lab Med","Lippi, Giuseppe","Plebani, Mario","32191623"],"abstract":["Coronavirus disease 2019, abbreviated to COVID-19 and sustained by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is the latest biological hazard to assume the relevance of insidious worldwide threat. One obvious question that is now engaging the minds of many scientists and healthcare professionals is whether and eventually how laboratory medicine could efficiently contribute to counteract this and other (future) viral outbreaks. Despite there being evidence that laboratory tests are vital throughout many clinical pathways, there are at least three major areas where in vitro diagnostics can also provide essential contributions to diagnostic reasoning and managed care of patients with suspected or confirmed SARS-CoV-2 infection. These include etiological diagnosis, patient monitoring, as well as epidemiologic surveillance. Nonetheless, some structural and practical aspects may generate substantial hurdles in providing timely and efficient response to this infectious emergency, which basically include inadequate (insufficient) environment and shortage of technical and human resources for facing enhanced volume of tests on many infected patients, some of whom are with severe disease. Some proactive and reactive strategies may hence be identified to confront this serious healthcare challenge, which entail major investments on conventional laboratory resources, reinforcement of regional networks of clinical laboratories, installation of mobile laboratories, as well as being proactive in establishing laboratory emergency plans."],"journal":"Clin Chem Lab Med","authors":["Lippi, Giuseppe","Plebani, Mario"],"date":"2020-03-20T11:00:00Z","year":2020,"_id":"32191623","week":"202012|Mar 16 - Mar 22","doi":"10.1515/cclm-2020-0240","keywords":["COVID-19","coronavirus","laboratory medicine","laboratory tests"],"source":"PubMed","topics":["Diagnosis","Prevention"],"weight":1,"_version_":1663352133759533056,"score":134.5177}]}